A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2017
At a glance
- Drugs Bimekizumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Sponsors UCB Biopharma
- 31 Aug 2017 Planned End Date changed from 1 Apr 2019 to 1 Nov 2018.
- 31 Aug 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Oct 2017.
- 10 Aug 2017 Status changed from recruiting to active, no longer recruiting.